Latest Breaking News On - Vera therapeutics - Page 5 : comparemela.com

Biotech Stocks Heat Up As Arvinas Scores Licensing Deal And Janux Reportedly Explores Options

Biotech Stocks Heat Up As Arvinas Scores Licensing Deal And Janux Reportedly Explores Options
investors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investors.com Daily Mail and Mail on Sunday newspapers.

Alpine immune sciencesVertex pharmaceuticalsArvinas therapeuticsJanux therapeuticsVera therapeutics

Vertex to Pay $4 9B for Kidney Disease Drug Developer

Vertex to Pay $4 9B for Kidney Disease Drug Developer
themiddlemarket.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themiddlemarket.com Daily Mail and Mail on Sunday newspapers.

United statesSami corwinWilliam blairMyles minterAlpine immune sciences incVera therapeutics incVertex pharmaceuticalsVertex pharmaceuticals incChinook therapeutics incAlpine immune sciencesBoston based vertexCrispr therapeuticsVera therapeuticsSemma therapeutics

Vera Therapeutics (NASDAQ:VERA) Sees Large Volume Increase

Vera Therapeutics, Inc. (NASDAQ:VERA – Get Free Report) saw strong trading volume on Thursday . 980,711 shares traded hands during trading, a decline of 21% from the previous session’s volume of 1,245,474 shares.The stock last traded at $43.49 and had previously closed at $41.62. Analysts Set New Price Targets A number of equities analysts have […]

Raymond jamesMaha katabiRoyal bankVera therapeutics company profileVera therapeutics incSecurities exchange commissionAmeritas investment partners incTower research capitalVera therapeuticsGet free reportDirector maha katabiExchange commissionResearch capitalInvestment partnersAmalgamated bankVera therapeutics daily

Vertex s Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept s Potential Impact - Vertex Pharmaceuticals (NASDAQ:VRTX)

Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion, expanding into nephrology with promising APOL1-mediated kidney disease treatments. Analysts foresee significant revenue growth potential, with Alpine's lead molecule poised to add over $5 billion in sales.

William blairAlpine immune sciences incVertex pharmaceuticals incorporatedVertex pharmaceuticalsAlpine immune sciencesVera therapeutics

Vertex Pharmaceuticals Nabs Alpine Immune Sciences In $4 9 Billion Deal

Vertex Pharmaceuticals Nabs Alpine Immune Sciences In $4 9 Billion Deal
investors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investors.com Daily Mail and Mail on Sunday newspapers.

United statesLeerink smithGeoff meachamThomas smithVertex pharmaceuticalsVertex pharmaceuticals adds to kidney diseases pipelineAlpine immune sciencesOtsuka pharmaceuticalVera therapeuticsAmerica securitiesLeerink partnersVertex pharmaceuticalChinook therapeuticsRelative strength ratingComposite rating